Cyclerion Therapeutics (CYCN) Invested Capital (2019 - 2025)
Historic Invested Capital for Cyclerion Therapeutics (CYCN) over the last 7 years, with Q3 2025 value amounting to $9.5 million.
- Cyclerion Therapeutics' Invested Capital rose 1634.55% to $9.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.5 million, marking a year-over-year increase of 1634.55%. This contributed to the annual value of $8.8 million for FY2024, which is 2159.82% down from last year.
- Per Cyclerion Therapeutics' latest filing, its Invested Capital stood at $9.5 million for Q3 2025, which was up 1634.55% from $8.6 million recorded in Q2 2025.
- Cyclerion Therapeutics' 5-year Invested Capital high stood at $65.2 million for Q2 2021, and its period low was $3.9 million during Q1 2023.
- Moreover, its 5-year median value for Invested Capital was $10.5 million (2022), whereas its average is $21.2 million.
- Its Invested Capital has fluctuated over the past 5 years, first crashed by 8940.16% in 2023, then soared by 15281.53% in 2024.
- Over the past 5 years, Cyclerion Therapeutics' Invested Capital (Quarter) stood at $48.2 million in 2021, then plummeted by 78.34% to $10.5 million in 2022, then grew by 8.0% to $11.3 million in 2023, then fell by 21.6% to $8.8 million in 2024, then increased by 7.77% to $9.5 million in 2025.
- Its last three reported values are $9.5 million in Q3 2025, $8.6 million for Q2 2025, and $8.8 million during Q1 2025.